PharmaCyte Biotech (PMCB) Equity Ratio (2016 - 2026)
PharmaCyte Biotech (PMCB) has disclosed Equity Ratio for 15 consecutive years, with 0.63 as the latest value for Q4 2025.
- On a quarterly basis, Equity Ratio fell 20.18% to 0.63 in Q4 2025 year-over-year; TTM through Oct 2025 was 0.63, a 20.18% decrease, with the full-year FY2025 number at 0.94, up 103.8% from a year prior.
- Equity Ratio was 0.63 for Q4 2025 at PharmaCyte Biotech, down from 0.97 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 1.0 in Q4 2021 to a low of 0.44 in Q1 2024.
- A 5-year average of 0.82 and a median of 0.92 in 2021 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: crashed 55.56% in 2024, then surged 108.87% in 2025.
- PharmaCyte Biotech's Equity Ratio stood at 1.0 in 2021, then dropped by 1.39% to 0.98 in 2022, then crashed by 52.63% to 0.47 in 2023, then skyrocketed by 69.18% to 0.79 in 2024, then fell by 20.18% to 0.63 in 2025.
- Per Business Quant, the three most recent readings for PMCB's Equity Ratio are 0.63 (Q4 2025), 0.97 (Q3 2025), and 0.94 (Q2 2025).